Alaunos Therapeutics
TCRT
89 hedge funds and large institutions have $7.36M invested in Alaunos Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 28 reducing their positions, and 17 closing their positions.
9,609% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $11K
0.03% less ownership
Funds ownership: 0.19% → 0.16% (-0.03%)
11% less funds holding
Funds holding: 100 → 89 (-11)
61% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 28
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
78% less capital invested
Capital invested by funds: $34.2M → $7.36M (-$26.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCA
Magnolia Capital Advisors
Jackson,
Mississippi
|
+$124K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$93.9K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$12.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$2.92M |
| 2 |
JP Morgan Chase
New York
|
-$694K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$262K |
| 4 |
Renaissance Technologies
New York
|
-$256K |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$115K |
TCRT Hedge Fund Activity: Q3 2023 in Review
89 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2023, worth a combined $7.36M — down 78% from $34.2M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TCRT and 6 opened new positions — a net loss of 11 holders — while 28 trimmed existing stakes and 11 added.
The largest buyer was Magnolia Capital Advisors, opening a new position worth an estimated $124K. The largest seller was Laurion Capital Management, exiting entirely with an estimated $2.92M sold.
- 89 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2023, down from 100 in Q2 2023.
- Funds reported $7.36M of Alaunos Therapeutics stock for Q3 2023, down 78% quarter-over-quarter.
- 6 funds opened new Alaunos Therapeutics positions in Q3 2023 and 17 closed out, a net change of -11 holders.
- The largest Alaunos Therapeutics buyer in Q3 2023 was Magnolia Capital Advisors, an estimated $124K added.
- The largest Alaunos Therapeutics seller in Q3 2023 was Laurion Capital Management, an estimated $2.92M sold.
Based on aggregated 13F filings for Q3 2023.